Canaccord analyst Whitney Ijem raised the firm’s price target on Wave Life Sciences (WVE) to $52 from $43 and keeps a Buy rating on the shares. The firm updated its model after meeting with management and getting updates on its pipeline including WVE-007 for obesity and WVE-006 in AATD.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Controversial Prasad leaving FDA, NYT reports
- Wave Life Sciences Bets on Data Over Near-Term Revenue
- Wave Life Sciences price target raised to $35 from $33 at Wedbush
- Citi opens ‘upside 30-day catalyst watch’ on Wave Life Sciences
- Wave Life Sciences: Differentiated Obesity Franchise and RNA-Editing Pipeline Momentum Justify Buy Rating